Search

Your search keyword '"Pego Reigosa, Robustiano"' showing total 46 results
Start Over Author "Pego Reigosa, Robustiano"
46 results on '"Pego Reigosa, Robustiano"'

4. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis

Author

Gonzalez-Gay, Miguel A., Vazquez-Rodriguez, Tomas R., Gomez-Acebo, Ines, Pego-Reigosa, Robustiano, Lopez-Diaz, Maria J., Vazquez-Trinanes, Matilde C., Miranda-Filloy, Jose A., Blanco, Ricardo, Dierssen, Trinidad, Gonzalez-Juanatey, Carlos, and Llorca, Javier

Subjects
Giant cell arteritis -- Diagnosis, Giant cell arteritis -- Complications and side effects, Giant cell arteritis -- Research, Stroke (Disease) -- Risk factors, Stroke (Disease) -- Research
Published
2009

7. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis

Author

Gonzalez-Gay, Miguel A., Pineiro, Angela, Gomez-Gigirey, Adriana, Garcia-Porrua, Carlos, Pego-Reigosa, Robustiano, Dierssen-Sotos, Trinidad, and Llorca, Javier

Subjects
Giant cell arteritis -- Prognosis, Giant cell arteritis -- Observations, Atherosclerosis -- Risk factors, Atherosclerosis -- Observations, Medical research, Medicine, Experimental
Published
2004

8. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study

Author

Gonzalez-Gay, Miguel A., Garcia-Porrua, Carlos, Pineiro, Angela, Pego-Reigosa, Robustiano, Llorca, Javier, and Hunder, Gene G.

Subjects
Giant cell arteritis -- Risk factors, Giant cell arteritis -- Causes of, Giant cell arteritis -- Research, Aortic aneurysms -- Risk factors, Aortic aneurysms -- Causes of, Aortic aneurysms -- Research, Medical research, Medicine, Experimental
Published
2004

12. Utilidad de los estudios serológicos en los centros de Atención Primaria para el diagnóstico precoz de la enfermedad de Lyme

Author

Universidade de Santiago de Compostela. Departamento de Patoloxía Animal, Vázquez López, María Esther, Fernández Rodríguez, Gonzalo, Díaz Fernández, Pablo, Díez Morrondo, María Carolina, Pego Reigosa, Robustiano, Coira Nieto, Amparo, Universidade de Santiago de Compostela. Departamento de Patoloxía Animal, Vázquez López, María Esther, Fernández Rodríguez, Gonzalo, Díaz Fernández, Pablo, Díez Morrondo, María Carolina, Pego Reigosa, Robustiano, and Coira Nieto, Amparo

Abstract

Objetivo: Determinar la utilidad del diagnóstico precoz de la enfermedad de Lyme (EL) en los Centros de Atención Primaria (CAP) empleando el ELISA como técnica de cribado serológico. Métodos: Se realiza un estudio retrospectivo (2006-2013) consistente en la determinación mediante ELISA de la seropositividad a Borrelia de 2.842 personas consideradas en riesgo de padecer EL. Se estudia la relación entre el hábitat y la zona de residencia de las personas con seropositividad a Borrelia, según la procedencia de las muestras (CAP/Hospital). Resultados: El 15,2% de los sueros resultaron positivos frente a Borrelia spp. La seropositividad fue significativamente superior en las muestras remitidas desde los CAP que desde el Hospital y en los habitantes del rural y la montana˜ frente al área urbana y la meseta. El porcentaje de seropositividad se incrementó con el transcurso de los anos. ˜ Los médicos de Atención Primaria detectaron mayor porcentaje de enfermos de Lyme en Fase I y tras la instauración del tratamiento no se observaron secuelas. Conclusiones: El papel del médico de atención primaria es primordial en el diagnóstico precoz de la EL, constatándose un mayor porcentaje de seropositivos entre las muestras remitidas desde los CAP con predominio del diagnóstico en Fase I de enfermedad y la resolución sin secuelas. La detección de anticuerpos específicos frente a Borrelia, mediante ELISA, es una prueba útil para el cribado de pacientes en riesgo de EL, Objective: The main aim of this study was to determine the usefulness of an early diagnosis of Lyme disease (LD) in Primary Health Care Centres (PHCC) using the ELISA test as serological screening technique. Methods: A retrospective study (2006-2013) was performed in order to determine the antiBorrelia seropositivity in 2,842 people at risk of having LD. The possible relationship between the environment and the area of residence with anti-Borrelia seropositivity was also studied according to the origin of the specimens (PHCC/Hospital). Results: Overall, 15.2% of samples were positive to Borrelia spp. Seropositivity was significantly higher in samples sent by PHCC doctors than those sent by Hospital doctors. Seropositivity was significantly higher in rural than in urban populations and in those who live in mountainous or flat areas. The percentage of seropositivity has increased over the years. Conclusions: The role of the PHCC doctor is essential for achieving an early diagnosis of Lyme disease, as a higher percentage of seropositives was detected in samples submitted from PHCC. Furthermore, most early localised LD patients were diagnosed in PHCC, avoiding the appearance of sequelae. Therefore, detection of Borrelia specific antibodies using an ELISA assay is a useful screening test for patients at risk of LD.

Published
2018

16. Utilidad de los estudios serológicos en los centros de Atención Primaria para el diagnóstico precoz de la enfermedad de Lyme

Author

Vázquez-López, María Esther, Fernández, Gonzalo, Díaz, Pablo, Díez-Morrondo, Carolina, Pego-Reigosa, Robustiano, and Coira-Nieto, Amparo

Abstract

Determinar la utilidad del diagnóstico precoz de la enfermedad de Lyme (EL) en los Centros de Atención Primaria (CAP) empleando el ELISA como técnica de cribado serológico.

Published
2024
Full Text
View/download PDF

18. Vogt Koyanagi Harada disease, our experience

Author

Pego Reigosa, Robustiano, Ramos Rúa, Laura, Alberte Woodword, Miguel, Guijarro del Amo, Mónica, Brañas Fernández, Francisco, Rodriguez Rodriguez, Maria, Nogueira Fernández, Victor, Gonzalez Ardura, Jessica, Cortés Laiño, José Antonio, Alvarez Fernandez, Leticia, and Da Silva França, Carlos Filipe

Published
2014

20. Manifestaciones articulares en enfermos de Lyme

Author

Vázquez-López, María Esther, primary, Díez-Morrondo, Carolina, additional, Sánchez-Andrade, Amalia, additional, Pego-Reigosa, Robustiano, additional, Díaz, Pablo, additional, and Castro-Gago, Manuel, additional

Published
2016
Full Text
View/download PDF

21. Epidemiología de la enfermedad de Lyme en un área sanitaria del noroeste de España

Author

Universidade de Santiago de Compostela. Departamento de Patoloxía Animal, Vázquez López, María Esther, Pego Reigosa, Robustiano, Díez Morrondo, María Carolina, Castro Gago, Manuel, Díaz Fernández, Pablo, Fernández Rodríguez, Gonzalo, Morrondo Pelayo, María Patrocinio, Universidade de Santiago de Compostela. Departamento de Patoloxía Animal, Vázquez López, María Esther, Pego Reigosa, Robustiano, Díez Morrondo, María Carolina, Castro Gago, Manuel, Díaz Fernández, Pablo, Fernández Rodríguez, Gonzalo, and Morrondo Pelayo, María Patrocinio

Abstract

Objetivo Valorar la influencia de algunos factores de riesgo sobre la tasa de incidencia de la enfermedad Lyme y describir las principales manifestaciones clínicas de esta. Métodos Se realizó un estudio retrospectivo sobre esta enfermedad (2006-2013), en una zona del noroeste de España, incluyendo solo los pacientes que cumplían los criterios de vigilancia epidemiológica de los Centers for Disease Control and Prevention de los Estados Unidos. Resultados La tasa de incidencia varió entre 2,64 y 11,61 por 100.000 habitantes y año. Hubo diferencias significativas respecto al hábitat, la edad y la zona de residencia. Los pacientes presentaron manifestaciones neurológicas (67,59%), dermatológicas (47,22%), reumatológicas (15,74%) o cardiacas (13,88%), solas o combinadas. Conclusiones El incremento de esta enfermedad en el noroeste de España y las diferencias observadas entre las distintas zonas de una misma área sanitaria hacen necesario plantear estudios epidemiológicos que permitan aumentar el índice de sospecha diagnóstica e implementar medidas de prevención eficaces., Objective To evaluate the influence of some risk factors on the incidence rate of Lyme disease and the main clinical manifestations. Methods A retrospective study of Lyme disease (2006-2013) was performed in north-west Spain; we included only patients who fulfilled the epidemiological surveillance criteria defined by the Centers for Disease Control and Prevention. Results The incidence rate varied between 2.64 and 11.61/100,000 inhabitants/year. Significant differences were found in relation to habitat, age and area of residence. Patients showed neurological (67.59%), dermatological (47.22%), rheumatological (15.74%) and cardiac (13.88%) manifestations, alone or combined. Conclusions Due to the increase of the disease in north-west Spain and the differences observed between the different areas, epidemiological studies are needed that increase the index of diagnostic suspicion and lead to the implementation of effective prevention measures.

Published
2015

23. Cardiac arrhythmia in cluster headache

Author

Pego Reigosa, Robustiano, Ramos Rúa, Laura, Alberte Woodword, Miguel, Brañas Fernández, Francisco, Nogueira Fernández, Victor, Cortés Laiño, José Antonio, and Alvarez Fernandez, Leticia

Published
2013
Full Text
View/download PDF

26. Experiencia clínica con lacosamida en Galicia: estudio GALACO

Author

Rodríguez Osorio, Xiana, primary, López González, Francisco Javier, additional, Pato Pato, Antonio, additional, Cebrián Pérez, Ernesto M., additional, Marey López, José Manuel, additional, Corredera García, Enrique, additional, Rubio Nazábal, Eduardo, additional, Castro Vilanova, Mª Dolores, additional, Abella Corral, Javier, additional, Rodríguez Regal, Ana, additional, Amigo Jorrín, Mª del Campo, additional, Pego Reigosa, Robustiano, additional, and en representación del grupo de est, en representación del grupo de est, additional

Published
2015
Full Text
View/download PDF

28. Manifestaciones articulares en enfermos de Lyme.

Author

Esther Vázquez-López, María, Díez-Morrondo, Carolina, Sánchez-Andrade, Amalia, Pego-Reigosa, Robustiano, Díaz, Pablo, and Castro-Gago, Manuel

Abstract

Copyright of Reumatología Clínica is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2016
Full Text
View/download PDF

29. Zonisamida en el tratamiento preventivo de la migraña refractaria

Author

Pascual Gómez, Julio, primary, Gracia Naya, Manuel, additional, Leira Muiño, Rogelio, additional, Mateos Marcos, Valentín, additional, Álvaro González, Luis Carlos, additional, Hernando, Ignacio, additional, Oterino Durán, Agustín, additional, Iglesias Díez, Fernando, additional, Caminero Rodríguez, Ana Belén, additional, García Moncó, Juan Carlos, additional, Forcea, Nerea, additional, Guerrero Peral, Ángel Luis, additional, Bueno, Valentín, additional, Santos García, Diego, additional, Pérez, Celia, additional, Blanco González, Miguel, additional, Pego Reigosa, Robustiano, additional, Rodríguez, Rosa, additional, Mederer Hengstl, Susana, additional, Pato Pato, Antonio, additional, Sánchez Herrero, Joaquín, additional, Maciñeiras Montero, José Luis, additional, Ortega, Fernando, additional, Arias, Mónica, additional, and Díaz González, Manuel, additional

Published
2010
Full Text
View/download PDF

35. Quiste del velum interpositum

Author

Vázquez López, María Esther, primary, Pego Reigosa, Robustiano, additional, Martínez Vázquez, Francisco, additional, and Armesto Pérez, Víctor, additional

Published
2003
Full Text
View/download PDF

36. Erdheim-Chester Disease with Spinal Cord Manifestations

Author

Pego-Reigosa, Robustiano, primary, Brañas-Fernández, Francisco, additional, Martínez-Vázquez, Francisco, additional, Rivas-Bande, María José, additional, Sanjuanbenito, Luís, additional, García-Villanueva, Mercedes, additional, and Cortés-Laíño, José Antonio, additional

Published
2000
Full Text
View/download PDF

40. Ischemic Heart Disease in Patients from Northwest Spain with Biopsy Proven Giant Cell Arteritis. A Population Based Study

Author

Gonzalez-Gay, Miguel, Rubiera, Gerardo, SJñeiro, Angela, Garcia-Porrua, Carlos, Pego-Reigosa, Robustiano, Gonzalez-Juanatey, Carlos, Sanchez-Andrade, Amalia, and Llorca, Javier

Abstract

OBJECTIVE: To assess the incidence, mortality, and predictors of ischemic heart disease (IHD) in patients from the Lugo region of Northwest Spain with biopsy-proven giant cell arteritis (GCA). METHODS: Retrospective study of patients with biopsy-proven GCA diagnosed from 1981 to 2001 at the single hospital for a population of 250,000 people. A survival analysis was performed. Hazard ratios and standardized mortality ratio (SMR) as well as predictors of IHD in patients with biopsy-proven GCA were also assessed. RESULTS: Nineteen (9%) of the 210 patients with biopsy-proven GCA diagnosed during the period of study had IHD. The incidence of IHD in patients with GCA was 12.6/1000 person-years at risk (95% CI 6.9–21.0). During the study period 1981–2000 the population aged ≥ 50 years in Lugo was roughly 100,000, and the mortality rate due to IHD in patients with GCA for that population was 8/100,000. The SMR in patients with GCA due to IHD was 1.62 (95% CI 0.70–3.20). Mortality in patients with GCA who had IHD was higher than in those patients without IHD (age and sex adjusted hazard ratio 2.81, 95% CI 1.51–5.21; p = 0.001). Age (hazard ratio 1.15), hypertension (hazard ratio 2.51), and abnormal temporal artery on physical examination (hazard ratio 0.36) at the time of diagnosis of GCA were the best predictors of IHD over the followup period in patients with biopsy-proven GCA. CONCLUSION: Our observations suggest that mortality due to IHD in patients from Lugo with GCA is not much higher than that reported in the Spanish population aged 50 years and older. However, mortality in patients with GCA with IHD is higher than in GCA patients without IHD.

Published
2005

44. [Clinical experience with lacosamide in Galicia: the GALACO study].

Author

Rodriguez-Osorio X, Lopez-Gonzalez FJ, Pato-Pato A, Cebrian-Perez E, Marey-Lopez J, Corredera-Garcia E, Rubio-Nazabal E, Castro-Vilanova MD, Abella-Corral J, Rodriguez-Regal A, Amigo-Jorrin MC, and Pego-Reigosa R

Subjects
Acetamides adverse effects, Adult, Anticonvulsants adverse effects, Drug Therapy, Combination, Female, Humans, Lacosamide, Male, Middle Aged, Nervous System Diseases chemically induced, Retrospective Studies, Sodium Channel Blockers adverse effects, Sodium Channel Blockers therapeutic use, Spain, Acetamides therapeutic use, Anticonvulsants therapeutic use, Epilepsy drug therapy
Abstract

Introduction: Lacosamide is a sodium channel blocker antiepileptic drug authorized as an adjunctive therapy for focal seizures in adolescents and adults., Aim: To analyze the efficacy and safety of lacosamide in Galicia according to its use in daily clinical practice., Patients and Methods: Retrospective observational study in patients who started treatment with lacosamide between January 2014 and June 2013 in 10 hospitals in Galicia, Spain. Its efficacy and safety at 3, 6 and 12 months after starting lacosamide was assessed., Results: We included 184 patients with a mean age of 44.2 ± 17.4 years old; 56.5% (n = 104) were male; 173 patients constituted the efficacy population. Mean duration of epilepsy was 18.8 ± 15.5 years. Seizure frequency was 2.5 ± 1.6 episodes/month. After 12 months, 68.2% of patients (n = 118) had >= 50% improvement (responders) and among them, 54 (45.8% of responder patients) were seizure free. Twenty-three percent (n = 43) suffered from adverse events after 12 months, being dizziness (10.3%) and instability (3.3%) the most frequently reported. After the 12 month visit, 87.5% of patients (n = 161) continued treatment with lacosamide., Conclusions: Lacosamide provides a very good efficacy and safety profile for patients with focal refractory epilepsy. High percentage of responders may be related to a less refractory population compared to other daily clinical practice studies. It constitutes an attractive therapeutic option for the treatment of focal epilepsies.

Published
2015

45. [Paroxysmal atrial fibrillation within the context of cluster headaches].

Author

Ramos-Rúa L, Álvarez-Fernández L, Nogueira-Fernández V, da Silva-Franca CF, Brañas-Fernández FM, Pego-Reigosa R, and Cortés-Laíño JA

Subjects
Amiodarone therapeutic use, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Atrial Fibrillation drug therapy, Atrial Fibrillation physiopathology, Autonomic Nervous System Diseases physiopathology, Cluster Headache drug therapy, Cluster Headache physiopathology, Flecainide therapeutic use, Humans, Hypothalamus, Posterior physiopathology, Male, Middle Aged, Models, Neurological, Oxygen Inhalation Therapy, Propranolol therapeutic use, Trigeminal Nerve physiopathology, Atrial Fibrillation etiology, Autonomic Nervous System Diseases complications, Cluster Headache etiology
Published
2015

46. [Zonisamide in the preventive treatment of refractory migraine].

Author

Pascual-Gómez J, Gracia-Naya M, Leira R, Mateos V, Alvaro-González LC, Hernando I, Oterino A, Iglesias--Díez F, Caminero A, García-Moncó JC, Forcea N, Guerrero-Peral AL, Bueno V, Santos-García D, Pérez C, Blanco M, Pego-Reigosa R, Rodríguez R, Mederer-Hengstl S, Pato-Pato A, Sánchez-Herrero J, Maciñeiras-Montero JL, Ortega F, Arias M, and Díaz-González M

Subjects
Adult, Aged, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Patient Satisfaction, Treatment Outcome, Young Adult, Zonisamide, Anticonvulsants therapeutic use, Isoxazoles therapeutic use, Migraine Disorders drug therapy, Migraine Disorders prevention & control
Abstract

Introduction: Chronic migraine refractory to preventive treatment is a common clinical situation in general neurology clinics. The aim is to analyse our experience with zonisamide in the preventive treatment of patients with frequent refractory migraine., Patients and Methods: Those patients with no response or intolerance to topiramate and at least one more preventative received zonisamide. This drug was increased 25 mg per week up to 200 mg/day. The efficacy of zonisamide was evaluated in terms of 'response' (reduction in attack frequency below 50%) at the third month of treatment., Results: Our series comprises a total of 172 patients, with ages ranging from 22 to 69 years. 85% were women. The final dosage of zonisamide was 50-200 mg/day, with the 100 mg/day being the most frequently administered dose. Zonisamide was efficacious (response) in 76 (44%) patients; response being excellent in 22 (13%). MIDAS score was reduced by 43.2%. Zonisamide was not tolerated by 27% of the patients, mainly due to subjective mental slowness or digestive symptoms., Conclusions: These results, obtained in a big sample of patients refractory or intolerant to topiramate and other preventatives, indicate that, at least in conditions of daily clinical practice, zonisamide, at relatively low dosages, is an option to be considered for the preventive treatment of patients with frequent migraine.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results